PL4041748T3 - Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1 - Google Patents
Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1Info
- Publication number
- PL4041748T3 PL4041748T3 PL20780745.4T PL20780745T PL4041748T3 PL 4041748 T3 PL4041748 T3 PL 4041748T3 PL 20780745 T PL20780745 T PL 20780745T PL 4041748 T3 PL4041748 T3 PL 4041748T3
- Authority
- PL
- Poland
- Prior art keywords
- agonists
- side effects
- peptide compounds
- reducing side
- reducing
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382856.3A EP3800195A1 (en) | 2019-10-03 | 2019-10-03 | Peptide compounds for reducing side effects of cb1 receptor agonists |
| PCT/EP2020/077642 WO2021064165A1 (en) | 2019-10-03 | 2020-10-02 | Peptide compounds for reducing side effects of cb1 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4041748T3 true PL4041748T3 (pl) | 2024-10-21 |
Family
ID=68281384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20780745.4T PL4041748T3 (pl) | 2019-10-03 | 2020-10-02 | Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12459973B2 (pl) |
| EP (2) | EP3800195A1 (pl) |
| JP (1) | JP7781422B2 (pl) |
| CN (1) | CN114641486B (pl) |
| AU (1) | AU2020360716B2 (pl) |
| CA (1) | CA3156280A1 (pl) |
| ES (1) | ES2984754T3 (pl) |
| PL (1) | PL4041748T3 (pl) |
| WO (1) | WO2021064165A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025252686A1 (en) | 2024-06-03 | 2025-12-11 | Universitat Pompeu Fabra | Compounds for the treatment of cannabis use disorder |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410949B2 (en) * | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| PT2878306T (pt) * | 2012-07-13 | 2019-02-06 | Proteimax Biotecnologia Ltda | Péptido modificado, ligando do recetor cb, kit, processo in vitro para avaliação das ligações do recetor cb, utilizações, composição farmacêutica para modular a atividade do recetor cb |
| WO2014015298A1 (en) * | 2012-07-20 | 2014-01-23 | The Regents Of The University Of California | Peripherally-acting cannabinoid receptor agonists for chronic pain |
| WO2016120843A1 (en) | 2015-01-29 | 2016-08-04 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
-
2019
- 2019-10-03 EP EP19382856.3A patent/EP3800195A1/en not_active Withdrawn
-
2020
- 2020-10-02 CN CN202080069052.8A patent/CN114641486B/zh active Active
- 2020-10-02 JP JP2022520668A patent/JP7781422B2/ja active Active
- 2020-10-02 ES ES20780745T patent/ES2984754T3/es active Active
- 2020-10-02 CA CA3156280A patent/CA3156280A1/en active Pending
- 2020-10-02 WO PCT/EP2020/077642 patent/WO2021064165A1/en not_active Ceased
- 2020-10-02 US US17/766,355 patent/US12459973B2/en active Active
- 2020-10-02 PL PL20780745.4T patent/PL4041748T3/pl unknown
- 2020-10-02 EP EP20780745.4A patent/EP4041748B1/en active Active
- 2020-10-02 AU AU2020360716A patent/AU2020360716B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3800195A1 (en) | 2021-04-07 |
| EP4041748C0 (en) | 2024-05-01 |
| WO2021064165A1 (en) | 2021-04-08 |
| EP4041748A1 (en) | 2022-08-17 |
| JP2023504765A (ja) | 2023-02-07 |
| EP4041748B1 (en) | 2024-05-01 |
| ES2984754T3 (es) | 2024-10-30 |
| CA3156280A1 (en) | 2021-04-08 |
| CN114641486B (zh) | 2025-04-01 |
| CN114641486A (zh) | 2022-06-17 |
| US20240059737A1 (en) | 2024-02-22 |
| AU2020360716A1 (en) | 2022-04-21 |
| US12459973B2 (en) | 2025-11-04 |
| JP7781422B2 (ja) | 2025-12-08 |
| AU2020360716B2 (en) | 2025-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286462A (en) | Protein tyrosine phosphatase inhibitors | |
| IL289534A (en) | Parp1 inhibitors | |
| IL280290A (en) | Il2 agonists | |
| IL282179A (en) | Protein tyrosine phosphatase inhibitors | |
| EP3843714C0 (en) | CD73 INHIBITORS | |
| EP4007752C0 (en) | Kif18a inhibitors | |
| EP4007753C0 (en) | Kif18a inhibitors | |
| EP4007756C0 (en) | KIF18A INHIBITORS | |
| EP3652329A4 (en) | COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| HUE057323T2 (hu) | Hemoglobin módosítására alkalmas 2-formil-3-hidroxi-feniloximetil-vegyületek | |
| DK4051688T3 (da) | Cd73-hæmmere | |
| EP3423451A4 (en) | INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING | |
| MA49908A (fr) | Composés inhibant la protéine mcl-1 | |
| EP3787635A4 (en) | CD73 INHIBITORS | |
| IL304110A (en) | Keap1–nrf2 protein–protein interaction inhibitors | |
| EP3999517A4 (en) | CD73 INHIBITORS | |
| EP3679031A4 (en) | INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING | |
| EP3980011C0 (en) | SARM1 HIBITORS | |
| IL290878A (en) | Protein based cannabis compositions | |
| EP3884940A4 (en) | Novel imidazole derivative | |
| EP3761962A4 (en) | EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS | |
| IL280047A (en) | Formulation of cannabinoid compounds | |
| EP4257597A4 (en) | LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS | |
| IL285546A (en) | Compounds and methods for reducing kcnt1 expression |